Open AccessInterstitial lung disease associated with capmatinib therapy in a patient with non‐small cell lung cancer harboring a skipping mutation of MET exon 14
Author(s) -
Kanemura Hiroaki,
Takeda Masayuki,
Shimizu Shigeki,
Nakagawa Kazuhiko
Publication year - 2021
Publication title -
thoracic cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.823
H-Index - 28
eISSN - 1759-7714
pISSN - 1759-7706
DOI - 10.1111/1759-7714.13790
Subject(s) - medicine , interstitial lung disease , lung cancer , exon , mutation , tyrosine kinase , lung , oncology , tyrosine kinase inhibitor , exon skipping , disease , cancer research , cancer , biology , receptor , gene , genetics , alternative splicing
Capmatinib is a MET tyrosine kinase inhibitor (TKI) that has recently been approved for the treatment of advanced non–small cell lung cancer (NSCLC) positive for skipping mutations of MET exon 14 ( MET ex14). Drug‐induced interstitial lung disease (ILD) is a relatively rare, but potentially serious, side effect of TKIs administered for lung cancer treatment. Here we report a case of capmatinib‐induced ILD in a patient with NSCLC harboring a MET ex14 skipping mutation. Capmatinib should be immediately discontinued if ILD is suspected, and treatment with corticosteroid should be considered.